Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Original HTML

Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

NEWS PROVIDED BY

Law Offices of Howard G. Smith

Aug 28, 2026, 16:20 ET

SHARE THIS ARTICLE

BENSALEM, Pa., Aug. 28, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK THERAPEUTICS, INC. (AARD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE OCTOBER 13, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?

The complaint filed in this class action alleges that between February 10, 2025 and May 14, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (i) ARD-101 was less safe than Defendants had led investors to believe; (ii) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Contact Us To Participate or Learn More:  

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:

Howard G. Smith, Esq.,

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Call us at: (215) 638-4847

Email us at: howardsmith@howardsmithlaw.com,

Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

howardsmith@howardsmithlaw.com

www.howardsmithlaw.com

SOURCE Law Offices of Howard G. Smith

21%

more press release views with 

Request a Demo

Class (B2B/B2C)
Ignore
Ingest Status
Rejected
Dedupe hash
3eedf57b7c0d06476fd7eba7663a0805
Press Eligible
No
Press Eligible Reason
[Retro-Cleanup] legal spam
Source Name
Unknown Company
Original Summary

<p>BENSALEM, Pa., Aug. 28, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK...</p>

IGEL erweitert mit Teguar-Hardware das Angebot an Endgeräten für das Gesundheitswesen und industrielle Umgebungen
Image File
Original HTML

IGEL erweitert mit Teguar-Hardware das Angebot an Endgeräten für das Gesundheitswesen und industrielle Umgebungen USA - Deutsch

NEWS PROVIDED BY

IGEL

Aug 28, 2026, 16:55 ET

SHARE THIS ARTICLE

Die speziell entwickelten medizinischen und industriellen Systeme von Teguar erweitern die Auswahl kompatibler Hardware für IGEL-Implementierungen in spezialisierten Einsatzumgebungen für Endgeräte.

FORT LAUDERDALE, Florida, 28. August 2026 /PRNewswire/ -- IGEL®, ein weltweit tätiges Softwareunternehmen, das die IGEL Adaptive Secure Endpoint Platform™ anbietet, gab heute bekannt, dass Teguar dem IGEL-Ready-Ökosystem beigetreten ist und ausgewählte Hardware für den Einsatz mit IGEL OS validiert wurde. Die Partnerschaft bietet Kunden zusätzliche Hardwareoptionen für den Einsatz von Endgeräten im Gesundheitswesen, in der Fertigung, in Lagern und anderen spezialisierten Betriebsumgebungen.

IGEL Expands Endpoint Options for Healthcare and Industrial Environments with Teguar Hardware

Teguar entwickelt Computersysteme speziell für Umgebungen, in denen herkömmliche Geräte die Anforderungen an Umgebungsbedingungen, Robustheit oder Arbeitsabläufe möglicherweise nicht erfüllen. Das Portfolio umfasst robuste und wasserdichte Industriecomputer sowie All-in-One-Computer und Tablets, die speziell für den Einsatz im Gesundheitswesen entwickelt wurden.

IGEL ergänzt diese Hardware durch IGEL OS, ein unveränderliches Betriebssystem für sicheren Endgerätezugriff, sowie durch die IGEL Universal Management Suite™ (UMS™), mit der sich Richtlinien, Konfigurationen, Softwarebereitstellung, Updates und Geräteflotten über verteilte Endgeräte hinweg zentral verwalten lassen.

„Unternehmen weiten den sicheren Zugriff auf Umgebungen aus, in denen die Zuverlässigkeit der Endgeräte, ihre physische Robustheit und eine zentrale Governance gleichermaßen entscheidend sind", sagte Jim Airdo, Bereichsleiter für strategische Allianzen auf Senior-Ebene bei IGEL. „Durch die Aufnahme von Teguar in das IGEL-Ready-Ökosystem bieten wir unseren Kunden eine größere Auswahl geprüfter Hardware und unterstützen sie gleichzeitig dabei, eine vertrauenswürdige sowie einheitlich verwaltete Endgeräteebene aufzubauen."

Das kombinierte Angebot richtet sich an Unternehmen, die drei Anforderungen miteinander in Einklang bringen müssen: Hardware, die für spezielle Betriebsumgebungen geeignet ist, eine sichere Basis für Endgeräte und eine zentrale Verwaltung verteilter Geräte.

In Fertigungs- und Industrieumgebungen eignet sich Teguar-Hardware für Anwendungsfälle, in denen Geräte unter Bedingungen, die sich von denen eines herkömmlichen Büros unterscheiden, zuverlässig funktionieren müssen. Im Gesundheitswesen können Teguar-Systeme gemeinsam genutzte Arbeitsbereiche, den klinischen Zugriff und andere Arbeitsabläufe unterstützen, für die speziell entwickelte Endgerätehardware erforderlich ist.

IGEL OS bietet eine unveränderliche Betriebsgrundlage, die von Grund auf dazu beiträgt, die Angriffsfläche der Endgeräte zu verringern. UMS™ bietet IT-Teams eine zentrale Kontrolle über die Endgerätekonfiguration und die Softwarebereitstellung und unterstützt sie dabei, die Konsistenz zwischen Geräten zu gewährleisten, die an verschiedenen Standorten und in unterschiedlichen Betriebsumgebungen eingesetzt werden.

„Unternehmen modernisieren ihre Endgerätestrategie weiter, und die Kombination aus dem unveränderlichen Betriebssystem von IGEL und der speziell entwickelten Hardware von Teguar schafft eine leistungsstarke Lösung für anspruchsvolle Umgebungen", sagte Kevin Jones, Bereichsleiter für globalen Vertrieb und Marketing bei Teguar. „Im Rahmen des IGEL-Ready-Programms haben Teguar und IGEL die Kompatibilität zwischen wichtigen medizinischen und industriellen Produkten von Teguar und IGEL OS sichergestellt, sodass Kunden zentral verwaltete, sichere Endgeräte zuverlässig bereitstellen können."

IGEL unterstützt Zero-Trust-konforme Architekturen, indem es die Geräteebene stärkt, auf der Zugriffsentscheidungen basieren. Auf validierter Teguar-Hardware kann IGEL OS als einheitliche, zentral verwaltete Basis für Endgeräte dienen und den Zugriff auf virtuelle Anwendungen, Cloud-Desktops, SaaS-Anwendungen, browserbasierte Arbeitsabläufe sowie betriebliche Systeme unterstützen.

Das IGEL-Ready-Programm hilft Kunden dabei, Technologien und Endgerätehardware zu identifizieren, die für den Einsatz mit IGEL-Lösungen validiert sind. Durch die Beteiligung von Teguar wird das Angebot an speziell entwickelter Hardware für Unternehmen erweitert, die IGEL im Gesundheitswesen, in der Fertigung, in der Industrie und in anderen spezialisierten Umgebungen einsetzen.

Weitere Informationen zu dieser Partnerschaft finden Sie hier:

Lesen Sie den Blog: IGEL begrüßt Teguar als zertifizierten Hardware-Anbieter

Entdecken Sie: https://teguar.com/igel/

Informationen zu IGEL

IGEL® ist ein weltweit tätiges Softwareunternehmen, das die IGEL Adaptive Secure Endpoint Platform™ anbietet, eine vertrauenswürdige und kontrollierte Endgeräteplattform für den sicheren Zugriff auf Cloud, VDI, DaaS, SaaS, sichere Browser, Unternehmensanwendungen sowie OT-Endgeräte. Die Grundlage bildet IGEL OS, ein unveränderliches Betriebssystem, das dazu beiträgt, die Angriffsfläche von Endgeräten zu verringern, einen bekanntermaßen intakten Endgerätezustand aufrechtzuerhalten und den sicheren Zugriff in verteilten Arbeitsumgebungen zu unterstützen. Über das IGEL Preventative Security Model® bietet die Plattform zusätzlich attestierte Workload-Bereitstellung, zentrale Governance sowie kontextbezogene Durchsetzung und stimmt die Endgerätesicherheit damit auf Zero-Trust- und SSE/SASE-Architekturen wichtiger IGEL-Ready-Partner ab.

IGEL Business Continuity & Disaster Recovery™ (BC&DR) unterstützt Unternehmen dabei, den sicheren Zugriff auf Windows-Endgeräte wiederherzustellen, die von Ransomware, anderen Cyberangriffen oder Ausfällen betroffen sind. IGEL wurde 2001 gegründet, hat seinen Hauptsitz in Deutschland sowie US-Niederlassungen in San Francisco und Fort Lauderdale und arbeitet mit einem Ökosystem aus 130 führenden Technologiemarken zusammen. Weitere Informationen finden Sie auf www.igel.com.

Windows ist eine Marke der Microsoft-Unternehmensgruppe.

21%

more press release views with 

Request a Demo

Ingest Status
Rewritten
Dedupe hash
a6d9179b11fc8aa6dc32cd34cb91f79a
Press Eligible
Yes
Press Eligible Reason
Business announcement about a partnership expanding validated hardware and secure endpoint technology for healthcare and industrial environments.
Source Name
Unknown Company
Original Summary

<p>Die speziell entwickelten medizinischen und industriellen Systeme von Teguar erweitern die Auswahl kompatibler Hardware für IGEL-Implementierungen in spezialisierten Einsatzumgebungen für Endgeräte. FORT LAUDERDALE, Florida, 28. August 2026 /PRNewswire/ -- IGEL®, ein weltweit tätiges...</p>

Image URL
https://mmx.prnewswire.com/media/MS1977280/IGEL-Teguar-Better-Together.jpg?id=OA2917429&p=facebook
First Horizon Executive Amy Perry Named Woman of Impact by the Mid-South Chapter of the American Heart Association
Image File
Original HTML

First Horizon Executive Amy Perry Named Woman of Impact by the Mid-South Chapter of the American Heart Association

NEWS PROVIDED BY

First Horizon Corporation

Aug 28, 2026, 17:00 ET

SHARE THIS ARTICLE

MEMPHIS, Tenn., Aug. 28, 2026 /PRNewswire/ -- First Horizon Corporation (NYSE: FHN) is pleased to announce that Amy Perry, Executive Vice President and Operations Executive, has been named a 2026 Woman of Impact by the Mid-South Chapter of the American Heart Association and Go Red for Women.

Amy Perry, First Horizon Corporation

In 2026, the sixth annual Woman of Impact campaign brought together 11 influential women to raise funds and awareness across the Memphis community, supporting the American Heart Association's mission to improve health and spread hope. This year's cohort raised a record-breaking $260,000 to support efforts focused on heart disease, stroke prevention and community health.

For Perry, raising awareness about cardiovascular health is the primary reason she chose to participate. Her family's experiences have made prevention and awareness especially meaningful.

"Heart disease and stroke and have affected my family in deeply personal ways," said Amy Perry, Executive Vice President and Operations Executive for First Horizon Corporation. "My mother battled high blood pressure, tachycardia and angina when I was growing up. As a teenager, I lost my father unexpectedly after he suffered a massive stroke and, years later, my brother died of a heart attack in his early 60s. These experiences have reinforced the importance of understanding our risk factors, how to recognize warning signs and the actions we all can take to protect our cardiovascular health."

In her role at First Horizon, Perry's leadership supports the company's commitment to serving clients, colleagues and communities across its footprint. Perry's dedication has earned her recognition on the Memphis Business Journal's Super Women in Business list and as a member of one of American Banker's Most Powerful Women in Banking Top Teams. Under her leadership, First Horizon Operations has been recognized with a Commitment Award from the Tennessee Center for Performance Excellence.

To learn more about the American Heart Association and how you can support Go Red for Women, visit www.goredforwomen.org.

About First Horizon

First Horizon Corp. (NYSE: FHN), with $84.4 billion in assets as of June 30, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.

SOURCE First Horizon Corporation

21%

more press release views with 

Request a Demo

Ingest Status
Rewritten
Dedupe hash
e22ee90f7aaaec73464338516275e86e
Press Eligible
Yes
Press Eligible Reason
Business news about a regional financial services company and its executive’s community recognition and fundraising efforts.
Source Name
Unknown Company
Original Summary

<p>MEMPHIS, Tenn., Aug. 28, 2026 /PRNewswire/ -- First Horizon Corporation (NYSE: FHN) is pleased to announce that Amy Perry, Executive Vice President and Operations Executive, has been named a 2026 Woman of Impact by the Mid-South Chapter of the American Heart Association and Go Red for...</p>

Image URL
https://mmx.prnewswire.com/media/MS1977647/Amy-Perry-Headshot.jpg?id=OA2918332&p=facebook
IGEL breidt met Teguar-hardware de endpointopties voor gezondheidszorg- en industriële omgevingen uit
Image File
Original HTML

IGEL breidt met Teguar-hardware de endpointopties voor gezondheidszorg- en industriële omgevingen uit USA - Nederlands

NEWS PROVIDED BY

IGEL

Aug 28, 2026, 17:23 ET

SHARE THIS ARTICLE

De speciaal voor dit doel ontwikkelde medische en industriële systemen van Teguar bieden compatibele hardwareopties voor IGEL-implementaties in gespecialiseerde endpointomgevingen

FORT LAUDERDALE, Fla., 28 augustus 2026 /PRNewswire/ -- IGEL®, een wereldwijd softwarebedrijf dat het IGEL Adaptive Secure Endpoint Platform™ levert, heeft vandaag aangekondigd dat Teguar zich heeft aangesloten bij het IGEL Ready-ecosysteem, met geselecteerde hardware die is gevalideerd voor gebruik met IGEL OS. Het partnerschap biedt klanten extra hardwareopties voor endpointimplementaties in de gezondheidszorg, productie, magazijnen en andere gespecialiseerde operationele omgevingen.

IGEL Expands Endpoint Options for Healthcare and Industrial Environments with Teguar Hardware

Teguar ontwikkelt speciaal ontworpen computersystemen voor omgevingen waar conventionele commerciële apparaten mogelijk niet voldoen aan de vereisten op het gebied van omgevingscondities, robuustheid of workflows. Het portfolio omvat robuuste en waterdichte industriële computers, evenals alles-in-ééncomputers en tablets die zijn ontworpen voor gebruik in gezondheidszorgomgevingen.

IGEL vult deze hardware aan met IGEL OS, een onveranderlijk besturingssysteem voor veilige endpointtoegang, en de IGEL Universal Management Suite™ (UMS™), die gecentraliseerd beleid, configuratie, softwarelevering, updates en beheer van apparatenparken in gedistribueerde endpointomgevingen mogelijk maakt.

"Organisaties breiden veilige toegang uit naar omgevingen waar endpointbetrouwbaarheid, fysieke duurzaamheid en gecentraliseerde governance allemaal van belang zijn", zei Jim Airdo, Senior VP of Strategic Alliances bij IGEL. "Door Teguar te verwelkomen in het IGEL Ready-ecosysteem, bieden we klanten meer gevalideerde hardwarekeuzes terwijl we hen helpen een vertrouwde en consistent beheerde endpointlaag op te zetten."

Het gecombineerde aanbod is ontworpen voor organisaties die drie vereisten moeten in evenwicht brengen: hardware die geschikt is voor gespecialiseerde operationele omgevingen, een veilige endpointbasis en gecentraliseerd beheer van gedistribueerde apparaten.

In productie- en industriële omgevingen kan Teguar-hardware toepassingen ondersteunen waarbij apparaten betrouwbaar moeten werken onder omstandigheden die afwijken van die in een traditionele kantooromgeving. In de gezondheidszorg kunnen Teguar-systemen gedeelde werkruimtes, klinische toegang en andere workflows ondersteunen waarvoor speciaal ontworpen endpointhardware nodig is.

IGEL OS biedt een onveranderlijke operationele basis die helpt het aanvalsoppervlak van endpoints vanuit het ontwerp te verkleinen. UMS™ geeft IT-teams gecentraliseerde controle over de configuratie van endpoints en de levering van software, waardoor ze consistentie kunnen handhaven tussen apparaten die in meerdere faciliteiten en operationele omgevingen worden ingezet.

"Organisaties blijven hun endpointstrategie moderniseren en de combinatie van het onveranderlijke besturingssysteem van IGEL met de speciaal ontwikkelde hardware van Teguar vormt een krachtige oplossing voor veeleisende omgevingen", zei Kevin Jones, Global VP Sales and Marketing bij Teguar. "Door het IGEL Ready-programma hebben Teguar en IGEL de compatibiliteit tussen de belangrijkste medische en industriële producten van Teguar en IGEL OS gewaarborgd, waardoor klanten centraal beheerde, beveiligde endpoints met vertrouwen kunnen implementeren."

IGEL ondersteunt op Zero Trust afgestemde architecturen door de apparaatslaag te versterken waarop toegangsbeslissingen zijn gebaseerd. Wanneer IGEL OS wordt ingezet op gevalideerde Teguar-hardware, kan het een consistente en centraal beheerde endpoint-basis bieden voor toegang tot virtuele applicaties, clouddesktops, SaaS-applicaties, browsergebaseerde workflows en operationele systemen.

Het IGEL Ready-programma helpt klanten technologieën en endpointhardware te identificeren die zijn gevalideerd voor gebruik met IGEL-oplossingen. De deelname van Teguar breidt het scala aan speciaal voor dit doel ontworpen hardware uit dat beschikbaar is voor organisaties die IGEL inzetten in de gezondheidszorg, productie, industrie en andere gespecialiseerde omgevingen.

Meer informatie over dit partnerschap vindt u hier:

Lees de blogpost: IGEL Welcomes Teguar as a Certified Hardware Provider

Ontdek meer: https://teguar.com/igel/ 

Over IGEL

IGEL®  is een wereldwijd softwarebedrijf dat het IGEL Adaptive Secure Endpoint Platform™ levert, een betrouwbaar en beheerd endpointplatform voor veilige toegang tot cloud, VDI, DaaS, SaaS, Secure Browsers, bedrijfsapplicaties en OT-endpoints. De basis daarvan is IGEL OS, een onveranderlijk besturingssysteem dat helpt het aanvalsoppervlak van endpoints te verkleinen, een bekende goede endpointtoestand te behouden en veilige toegang te ondersteunen in gedistribueerde werkomgevingen. Via het IGEL Preventative Security Model® voegt het platform geattesteerde workloadlevering, gecentraliseerde governance en contextuele handhaving toe, waarbij endpointbeveiliging wordt afgestemd op Zero Trust en SSE/SASE-architecturen van belangrijke IGEL Ready-partners.

IGEL Business Continuity & Disaster Recovery™ (BC&DR) helpt organisaties veilige toegang te herstellen op Windows-endpoints die getroffen zijn door ransomware, andere cyberaanvallen of storingen. IGEL, opgericht in 2001, heeft zijn hoofdkantoor in Duitsland en Amerikaanse kantoren in San Francisco en Fort Lauderdale en werkt samen met een ecosysteem van 130 toonaangevende technologiemerken. Meer informatie vindt u op www.igel.com.

Windows is een handelsmerk van de Microsoft-groep.

21%

more press release views with 

Request a Demo

Ingest Status
Rewritten
Dedupe hash
dc79e78f7b702c2ff15fadc339eeaa5e
Press Eligible
Yes
Press Eligible Reason
Zakelijk technologienieuws over een partnership tussen IGEL en Teguar, met gevalideerde hardware en endpointoplossingen voor gezondheidszorg en industriële omgevingen.
Source Name
Unknown Company
Original Summary

<p>De speciaal voor dit doel ontwikkelde medische en industriële systemen van Teguar bieden compatibele hardwareopties voor IGEL-implementaties in gespecialiseerde endpointomgevingen FORT LAUDERDALE, Fla., 28 augustus 2026 /PRNewswire/ -- IGEL®, een wereldwijd softwarebedrijf dat het IGEL...</p>

Image URL
https://mmx.prnewswire.com/media/MS1977280/IGEL-Teguar-Better-Together.jpg?id=OA2917421&p=facebook
Independent Leadership Council Groups Surpass $10 Million in Funding
Image File
Original HTML

Independent Leadership Council Groups Surpass $10 Million in Funding

NEWS PROVIDED BY

Independent Leadership Council

Aug 28, 2026, 17:41 ET

SHARE THIS ARTICLE

WASHINGTON, Aug. 28, 2026 /PRNewswire/ -- The Independent Leadership Council (ILC), a national organization co-founded by Heather Manchin, Adam Brandon and Seth Cohen to support independent leaders in Congress, along with its related PAC, announced today that it has raised more than $10 million since its launch in July, demonstrating growing momentum and support for an alternative to the two-party gridlock that has come to define American politics.

The funding comes from a broad coalition of Democrats, Republicans and independents united by a shared conviction: the political system no longer reflects the people it serves. Nearly half of Americans identify as independent or unaffiliated, and in 106 congressional districts and 16 states, unaffiliated voters outnumber voters registered with either major party. Yet today, not one member of Congress was elected as an independent and governs without caucusing with either party. That is an extraordinary disconnect between the country and the people representing it.

The ILC believes this convergence of growing independent identification, deep dissatisfaction with both parties and historically narrow congressional margins has created a unique opening for independent leadership. In a closely divided Congress, it doesn't take dozens of independents to change the dynamic. It only takes a few members of Congress to shift the balance of power away from the parties and to the people.

"We have seen what can happen when neither party can take a consequential vote for granted, and Senator Manchin brings invaluable lived experience of exactly that to the leadership of this effort," said Adam Brandon, co-founder of the Independent Leadership Council. Brandon continued, "For years, Americans have said they want better choices. We want  to prove those choices can win and go on to make a real difference. A few true independents in a closely divided Congress can shift meaningful leverage away from party leadership and back toward the people, demonstrating an entirely new model for governing. Surpassing $10 million gives us the resources to begin proving it."

Heather Manchin added, "Independent leadership isn't about standing alone. It's about having the freedom to think independently and the leverage to bring both sides to the table. We aren't trying to replace the Republican Party or the Democratic Party, and we aren't building another party. We're creating the conditions for leaders to answer to the people who elected them instead of the political machinery that too often determines who runs, who wins and how Washington governs." Manchin continued, "We fully expect to double our current number in the weeks ahead as the candidates we support demonstrate that they can win and will change the way Washington operates by refusing to caucus with either party."

The ILC's mission rests on three commitments: restoring fair competition to a political system currently controlled by two parties that protect incumbents over voters; supporting leaders willing to find real solutions instead of engaging in partisan gridlock; and holding elected officials genuinely accountable to the people they serve, not to party leadership.

In the coming weeks, the ILC and Independent PAC will announce support for a slate of independent candidates running for the U.S. House and Senate, with the strongest opportunities coming out of the West and Midwest. What unites these candidates is not ideology, but a shared commitment: each is pledging not to caucus with either party once elected. In addition, each candidate has expressed a willingness to work to find common-sense solutions to the challenges facing America today and has a viable path to victory.

The ILC was launched in July following a national convening at The Greenbrier in West Virginia, bringing together leaders, funders, and independent candidates from across the country under a shared platform focused on fair competition, common-sense solutions, and government accountability.

About the Independent Leadership Council

The Independent Leadership Council is a national organization dedicated to supporting independent-minded leaders in Congress who refuse to caucus with either political party and commit to full transparency and accountability to the voters they serve. Learn more.

Independent PAC is a federal hybrid PAC dedicated to supporting independent candidates through independent advocacy efforts. Learn More.

Media Contacts:

Alex Comisar | acomisar@actumllc.com | (214) 728-4909

Liam Dineen-Herzog | ldineenherzog@actumllc.com | (475) 204-1155

SOURCE Independent Leadership Council

21%

more press release views with 

Request a Demo

Class (B2B/B2C)
Ignore
Ingest Status
Error
Dedupe hash
040d122742f0a7224dafbfff12b1faf3
Press Eligible
No
Press Eligible Reason
Political organization funding and candidate support announcement.
Source Name
Unknown Company
Original Summary

<p>WASHINGTON, Aug. 28, 2026 /PRNewswire/ -- The Independent Leadership Council (ILC), a national organization co-founded by Heather Manchin, Adam Brandon and Seth Cohen to support independent leaders in Congress, along with its related PAC, announced today that it has raised more than $10...</p>

Image URL
https://mmx.prnewswire.com/media/MS1977865/ILC-Logo-Black.jpg?id=OA2918839&p=facebook
Robbins LLP Urges AARD Stockholders Who Lost Money Investing in Aardvark Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action
Image File
Original HTML

Robbins LLP Urges AARD Stockholders Who Lost Money Investing in Aardvark Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

NEWS PROVIDED BY

Robbins LLP

Aug 28, 2026, 17:42 ET

SHARE THIS ARTICLE

SAN DIEGO, Aug. 28, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies designed to inhibit hunger and treat metabolic diseases such as Prader-Willi Syndrome ("PWS"), a neurodevelopmental disorder condition that presents hyperphagia, or a feeling of extreme, insatiable hunger.

The complaint alleges that Aardvark misled investors regarding the viability and efficacy of its lead drug candidate ARD-101.

Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information about becoming lead plaintiff.

Listen to our podcast.

Why Was Aardvark Therapeutics Sued?

The complaint alleges that the Company's lead product candidate is ARD-101, which defendants have repeatedly described as a "gut-restricted" small-molecule agonist of certain TAS2Rs expressed in the gut lumen. To evaluate the effect of ARD-101on hyperphagia-related behavior in patients with Prader-Willi Syndrome, defendants commenced both a Phase 3 clinical trial, referred to as the HERO trial, and an open-label extension.

The Offering Documents in support of the IPO informed investors that the preclinical data concerning ARD-101 "suggest that ARD-101 shows potential to be a well-tolerated, satiety-inducing drug."

Notwithstanding, the complaint alleges that defendants failed to disclose that:

ARD-101 was less safe than defendants had led investors to believe;

accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and

as a result, defendants' public statements were materially false and misleading at all relevant times.

Why Did AARD Stock Drop?

The complaint alleges that on February 27, 2026, Aardvark issued a press release "announc[ing] it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial." Aardvark attributed the decision to "reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study" and said that it "has voluntarily paused ongoing enrollment and dosing in the HERO trial" while "conducting a comprehensive review of the data to inform next steps." On this news, Aardvark's stock price fell $7.02 per share, or 56.2%, to close at $5.47 per share on March 2, 2026.

Then, on May 14, 2026, Aardvark issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company's previously announced voluntary pause." The press release specified that "[t]he clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the Phase 3 open-label extension (OLE) trial (AVK-101-302)." On this news, Aardvark's stock price fell $2.16 per share, or 32.1%, to close at $4.57 per share on May 15, 2026.

Who May Be Eligible to Participate in the AARD Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired

AARD common stock pursuant to the Company's February 13, 2025 IPO; and/or

AARD securities between February 13, 2025 and May 14, 2026

Investors who suffered losses during that period may have legal rights under the federal securities laws.

What Is a Lead Plaintiff?

The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Serving as lead plaintiff is not required to share in any potential recovery. Investors who do not seek appointment may remain absent class members if the case proceeds and later resolves successfully.

Stockholders who wish to seek appointment as lead plaintiff must do so by October 13, 2026.

Does it cost anything to participate?

No. Robbins LLP represents investors on a contingency fee basis.

Contact Robbins LLP

Investors seeking additional information about the Aardvark Therapeutics securities class action may contact Robbins LLP by submitting an inquiry.

About Robbins LLP

Robbins LLP is a shareholder rights law firm focused on representing investors in securities fraud and shareholder litigation. The firm has helped recover more than $1 billion for investors, obtained significant corporate governance reforms, and has represented shareholders in cases involving alleged violations of the federal securities laws.

"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Aardvark Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

SOURCE Robbins LLP

21%

more press release views with 

Request a Demo

Class (B2B/B2C)
Ignore
Ingest Status
Rejected
Dedupe hash
73a965bfe57a1a9d0a5ced348614d70a
Press Eligible
No
Press Eligible Reason
[Retro-Cleanup] legal spam
Source Name
Unknown Company
Original Summary

<p>SAN DIEGO, Aug. 28, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's...</p>

Image URL
https://mmx.prnewswire.com/media/MS559099/Robbins-LLP-Logo.jpg?id=OA2918577&p=facebook
Cohen &amp; Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
Original HTML

Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)

NEWS PROVIDED BY

Cohen & Steers, Inc.

Aug 28, 2026, 17:47 ET

SHARE THIS ARTICLE

NEW YORK, Aug. 28, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources of the distribution to be paid on August 31, 2026 and cumulative distributions paid fiscal year-to-date.

In December 2021, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund's shares. 

The Fund's monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund's assets. A return of capital is not taxable; rather, it reduces a shareholder's tax basis in his or her shares of the Fund. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund's distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund's distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

August 2026

YEAR-TO-DATE (YTD)

August 31, 2026*

Source

Per Share

Amount

% of Current

Distribution

Per Share

Amount

% of 2026

Distributions

Net Investment Income

$0.0342

39.31 %

$0.2481

35.65 %

Net Realized Short-Term Capital Gains

$0.0000

0.00 %

$0.0000

0.00 %

Net Realized Long-Term Capital Gains

$0.0528

60.69 %

$0.4479

64.35 %

Return of Capital (or other Capital Source)

$0.0000

0.00 %

$0.0000

0.00 %

Total Current Distribution

$0.0870

100.00 %

$0.6960

100.00 %

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's managed distribution policy.  The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES.

The Fund's Year-to-date Cumulative Total Return for fiscal year 2026 (January 1, 2026 through July 31, 2026) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund's Cumulative Distribution Rate for 2026. In addition, the Fund's Average Annual Total Return for the five-year period ending July 31, 2026 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund's Current Annualized Distribution Rate for 2026. The performance and distribution rate information disclosed in the table is based on the Fund's net asset value per share (NAV). The Fund's NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's individual investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market. 

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2026 to July 31, 2026                                                                 

Year-to-date Cumulative Total Return1

6.68 %

Cumulative Distribution Rate2

5.17 %

Five-year period ending July 31, 2026

Average Annual Total Return3

8.08 %

Current Annualized Distribution Rate4

7.75 %

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund's NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund's current fiscal period (January 1, 2026 through August 31, 2026) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund's NAV as of July 31, 2026.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending July 31, 2026. Annual NAV Total Return is the percentage change in the Fund's NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period's distribution rate annualized as a percentage of the Fund's NAV as of July 31, 2026.

Investors should consider the investment objectives, risks, charges and expense of the Fund carefully before investing. You can obtain the Fund's most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission's EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided here in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.  

Forward-Looking Statements

This press release and other statements that Cohen & Steers may make may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect the company's current views with respect to, among other things, its operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates," or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Website: https://www.cohenandsteers.com 

Symbol: (NYSE: CNS)

SOURCE Cohen & Steers, Inc.

21%

more press release views with 

Request a Demo

Ingest Status
Rewritten
Dedupe hash
1a375896ec9572aa5343b2921a59f772
Press Eligible
Yes
Press Eligible Reason
Business and financial announcement detailing a closed-end fund’s distribution sources, performance, and managed distribution policy.
Source Name
Unknown Company
Original Summary

<p>NEW YORK, Aug. 28, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources of the distribution to be paid on August 31, 2026 and cumulative distributions paid fiscal...</p>

Cohen &amp; Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
Original HTML

Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)

NEWS PROVIDED BY

Cohen & Steers, Inc.

Aug 28, 2026, 17:51 ET

SHARE THIS ARTICLE

NEW YORK, Aug. 28, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the distribution to be paid on August 31, 2026 and cumulative distributions paid fiscal year-to-date.

In March 2015, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund's shares. 

The Fund's monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund's assets. A return of capital is not taxable; rather, it reduces a shareholder's tax basis in his or her shares of the Fund. In addition, distributions from the Fund's investments in MLPs are attributed to various sources, including net investment income and return of capital. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund's distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund's distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

August 2026

YEAR-TO-DATE (YTD)

August 31, 2026*

Source

Per Share

Amount

% of Current

Distribution

Per Share

Amount

% of 2026

Distributions

Net Investment Income

$0.0000

0.00 %

$0.5641

43.73 %

Net Realized Short-Term Capital Gains

$0.0000

0.00 %

$0.0000

0.00 %

Net Realized Long-Term Capital Gains

$0.1650

100.00 %

$0.7259

56.27 %

Return of Capital (or other Capital Source)

$0.0000

0.00 %

$0.0000

0.00 %

Total Current Distribution

$0.1650

100.00 %

$1.2900

100.00 %

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's managed distribution policy.  The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES.

The Fund's Year-to-date Cumulative Total Return for fiscal year 2026 (January 1, 2026 through July 31, 2026) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund's Cumulative Distribution Rate for 2026. In addition, the Fund's Average Annual Total Return for the five-year period ending July 31, 2026 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund's Current Annualized Distribution Rate for 2026. The performance and distribution rate information disclosed in the table is based on the Fund's net asset value per share (NAV). The Fund's NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's individual investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market. 

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2026 to July 31, 2026                                                                      

Year-to-date Cumulative Total Return1

14.68 %

Cumulative Distribution Rate2

4.58 %

Five-year period ending July 31, 2026

Average Annual Total Return3

8.87 %

Current Annualized Distribution Rate4

7.03 %

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund's NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund's current fiscal period (January 1, 2026 through August 31, 2026) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund's NAV as of July 31, 2026.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending July 31, 2026. Annual NAV Total Return is the percentage change in the Fund's NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period's distribution rate annualized as a percentage of the Fund's NAV as of July 31, 2026.

Investors should consider the investment objectives, risks, charges and expense of the Fund carefully before investing. You can obtain the Fund's most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission's EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided here in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.  

Forward-Looking Statements

This press release and other statements that Cohen & Steers may make may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect the company's current views with respect to, among other things, its operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates," or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Website: https://www.cohenandsteers.com 

Symbol: (NYSE: CNS)

SOURCE Cohen & Steers, Inc.

21%

more press release views with 

Request a Demo

Ingest Status
Rewritten
Dedupe hash
89fa40d35b73a935c5426bfcf0114aa5
Press Eligible
Yes
Press Eligible Reason
Business and financial news detailing a publicly traded infrastructure fund’s distribution, performance, and shareholder reporting.
Source Name
Unknown Company
Original Summary

<p>NEW YORK, Aug. 28, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the distribution to be paid on August 31, 2026 and cumulative distributions paid fiscal...</p>

PLAB Deadline: PLAB Investors with Losses in Excess of $100K Have Opportunity to Lead Photronics, Inc. Securities Fraud Lawsuit
Image File
Original HTML

PLAB Deadline: PLAB Investors with Losses in Excess of $100K Have Opportunity to Lead Photronics, Inc. Securities Fraud Lawsuit

NEWS PROVIDED BY

THE ROSEN LAW FIRM, P. A.

Aug 28, 2026, 17:52 ET

SHARE THIS ARTICLE

NEW YORK, Aug. 28, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Photronics, Inc. (NASDAQ: PLAB) between December 10, 2025 and May 27, 2026, inclusive (the "Class Period"), of the important September 4, 2026 lead plaintiff deadline.

So what: If you purchased Photronics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Photronics class action, go to https://rosenlegal.com/cases/photronics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 4, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Photronics' high-end product pipeline, customer schedules, and the stability of the alleged demand for its products; notably, that the seasonal recovery and design release momentum following the Chinese New Year holiday, which Photronics was claiming would develop, had stalled. Photronics was experiencing a critical bottleneck in its design release pipeline that rendered its forward growth expectations unachievable. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Photronics class action, go to https://rosenlegal.com/cases/photronics-inc/join   or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     case@rosenlegal.com

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

21%

more press release views with 

Request a Demo

Class (B2B/B2C)
Ignore
Ingest Status
Rejected
Dedupe hash
cb3652ea841aa864eaa6238909721292
Press Eligible
No
Press Eligible Reason
[Retro-Cleanup] legal spam
Source Name
PLAB Deadline
Original Summary

<p>NEW YORK, Aug. 28, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Photronics, Inc. (NASDAQ: PLAB) between December 10, 2025 and May 27, 2026, inclusive (the "Class Period"), of the important September 4, 2026 lead plaintiff...</p>

Image URL
https://mmx.prnewswire.com/media/MS1118010/Rosen-Law-Firm-Logo.jpg?id=OA2914752&p=facebook
Kommentar von "nd.DerTag" zur Lage im Iran-Krieg
Image File
Original HTML

28.08.2026 – 17:45

 

nd.DerTag / nd.DieWoche

 

Kommentar von "nd.DerTag" zur Lage im Iran-Krieg

 

Berlin (ots)

 

enau sechs Monate liegen der Iran auf der einen Seite sowie die USA und Israel auf der anderen miteinander im Krieg, ausgelöst durch einen völkerrechtlichen Angriff ohne Kriegserklärung auf die Islamische Republik. Für die USA ist das fast normal: Regierungen in Washington sind geübt darin, ein Land als gefährlich für die eigenen Interessen darzustellen, um es dann mit Bomben zu überziehen. Venezuela oder der Irak sind dafür bekannte Beispiele.

 

Wie der Iran-Krieg weitergehen wird, ist indes völlig unklar. Die US-Regierung hat offensichtlich keine Strategie und auch kein klares Kriegsziel. Die Straße von Hormus bleibt für den Schiffsverkehr blockiert und der Iran ist gewillt, nicht klein beizugeben. Doch die Islamische Republik als Sieger im Krieg zu bezeichnen, wie es Beobachter und Analysten seit Wochen tun, ist eine recht verquere Auffassung darüber, wie man als Sieger aus einem militärischen Konflikt hervorgeht. Über 4000 Menschen sind durch die Bombardements der USA und Israels ums Leben gekommen, die Infrastruktur wurde erheblich in Mitleidenschaft gezogen. Die Kriegsschäden sollen die 200-Milliarden-Dollar-Marke weit überschritten haben. Israelische und US-amerikanische Opfer des Krieges summieren sich dabei auf nicht mal einhundert Menschen - wohlgemerkt jeder einer zu viel.

 

Nur weil der Iran die Meerenge von Hormus zu kontrollieren in der Lage ist und so weltweit die Kosten für Erdöl und Dünger steigen lässt, ist das Land sicher kein Gewinner - auch wenn es sich selbst gerne so präsentiert. Es klingt mindestens zynisch, dem Iran einen Sieg anzudichten, nur weil man in West und Ost mehr bezahlen muss fürs Benzin an der Tankstelle. Man wird den Eindruck nicht los, dass die Experten schlicht enttäuscht sind über den Status quo, der nicht das ist, was sich viele versprochen hatten: den Sturz des iranischen Regimes.

 

Nach dieser Logik ist es mit dem im internationalen Recht als vielleicht höchstes Prinzip verankerten Gewaltverbots nicht weit her. Das Zusammenbrechen der Islamischen Republik unter den Bomben der USA und Israels hätte im politischen Diskurs rückwirkend als Legitimation für diesen und auch zukünftige Kriege gedient und all jene in der Auffassung bestätigt, dass eine interventionistische Außenpolitik, wenn sie denn ein sogenanntes Unrechtsregime wegfegt, gerechtfertigt sei, ja den Rechtsbruch sogar heilt. Das tut sie nicht. Es ist einfacher, hier von Imperialismus zu sprechen.

 

Gewinner sind sicher die Mineralölkonzerne und die Waffenproduzenten. Die USA werden ihre Waffendepots mit Großaufträgen auffüllen müssen; auch in die Taschen von Shell, Aral und Total fließt mehr Geld. Der "normale" Iraner und die "normale" Iranerin haben keinerlei Vorteile aus dem Krieg ziehen können. Die innerstaatliche Repression läuft weiter, ein Sturz der Islamischen Republik scheint zum derzeitigen Zeitpunkt ausgeschlossen und die Beziehungen zu den Nachbarstaaten sind an einem Tiefpunkt angelangt. Und während das US-Militär die Bomben über Teheran, Isfahan oder Bandar Abbas abwarf, ließ das iranische Regime über 500 Menschen hinrichten.

 

Pressekontakt:

 

nd.DerTag / nd.DieWoche

Redaktion

 

Telefon: 030/2978-1722

 

Original-Content von: nd.DerTag / nd.DieWoche, übermittelt durch news aktuell

Class (B2B/B2C)
Ignore
Ingest Status
Error
Dedupe hash
12e43d543e752ae3f120b20bba2f076e
Press Eligible
No
Press Eligible Reason
Politischer Kommentar zur Lage im Iran-Krieg ohne eigenständige Wirtschafts- oder Unternehmensnachrichten.
Source Name
Unknown Company
Original Summary

nd.DerTag / nd.DieWoche: Berlin (ots) - enau sechs Monate liegen der Iran auf der einen Seite sowie die USA und Israel auf der anderen miteinander im Krieg, ausgelöst durch einen völkerrechtlichen Angriff ohne Kriegserklärung auf die Islamische Republik. Für die USA ist ...

Image URL
https://cache.pressmailing.net/thumbnail/big/77893ebe-8fb8-4ce5-a540-5b12c390bfb3/logo